PI3K/AKT/mTOR is the key downstream pathway of most RTKs [6] and is hyperactivated in ~60% of breast cancer patients due to increased expression of growth factors and their receptors or genetic alterations in PIK3CA, AKT, and PTEN [7]. This evidence concerns the gene PIK3CA and breast cancer.